<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605941</url>
  </required_header>
  <id_info>
    <org_study_id>epigene-13151</org_study_id>
    <nct_id>NCT02605941</nct_id>
  </id_info>
  <brief_title>DNA Methylation Biomarkers for Cervical Cancer Screening</brief_title>
  <official_title>DNA Methylation Biomarkers for Cervical Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iStat Biomedical CO., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Li Shin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iStat Biomedical CO., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective study is to evaluate whether DNA methylation can be applied
      in cervical cancer screening.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of DNA methylation in identification of CIN3 or worse.</measure>
    <time_frame>3 years</time_frame>
    <description>Patient's information, including clinical diagnosis and the molecular testing results etc., will be collected. Performances of the screening tools will be compared.</description>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Cervical Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cervical cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Investigators plan to recruit 5,000 women to participate this study in Taiwan. Papanicolaou
        test, high-risk HPV typing and DNA methylation will be co-tested. It is expected to find an
        optimal solution for molecular cervical cancer screening. The participant will be recruited
        by Mackay Memorial Hospital, Chang Gung Memorial Hospital, and Lin-Hsin Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with age â‰¥20 and sexual experience

          -  Agree to sign ICF

        Exclusion Criteria:

          -  women had received Hysterectomy

          -  women had destructive therapy for cervical lesions in 6 months, for examples:
             conization, Laser or cryotherapy, chemotherapy, and radiation therapy

          -  Women are at pregnancy or had baby delivery in 6 weeks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuh-cheng Yang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mackay Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shih-chu Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Li Shin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ting-Chang Chang, MD., MPH.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Long Chang, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mackay Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chien-Ping Hung</last_name>
    <phone>+886-2-2696-3518</phone>
    <phone_ext>15</phone_ext>
    <email>apple@istatbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hsiu-yuan Tsao</last_name>
    <phone>+886-2-2696-3518</phone>
    <phone_ext>14</phone_ext>
    <email>hytsao@istatbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mackay Memorial Hospital, Linkou Chang Gung Memorial Hospital, Lin-Shin Medical Corporation Lin-Shin Hosptial</name>
      <address>
        <city>Taipei, Taoyuan, and Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yuh-cheng Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shih-chu Ho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting-Chang Chang, MD., MPH.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Long Chang, MD, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):114-23.</citation>
    <PMID>16434596</PMID>
  </reference>
  <reference>
    <citation>Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW, Chu TY, Sun CA, Chang CC, Yu MH. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008 Jul 1;123(1):161-7. doi: 10.1002/ijc.23519.</citation>
    <PMID>18398837</PMID>
  </reference>
  <reference>
    <citation>Huang TH, Lai HC, Liu HW, Lin CJ, Wang KH, Ding DC, Chu TY. Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. Int J Gynecol Cancer. 2010 May;20(4):513-9. doi: 10.1111/IGC.0b013e3181c7fe6e.</citation>
    <PMID>20442585</PMID>
  </reference>
  <reference>
    <citation>Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, Su PH, Liu YL, Yu MH. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer. 2010 Sep 15;116(18):4266-74. doi: 10.1002/cncr.25252.</citation>
    <PMID>20564139</PMID>
  </reference>
  <reference>
    <citation>Chao TK, Ke FY, Liao YP, Wang HC, Yu CP, Lai HC. Triage of cervical cytological diagnoses of atypical squamous cells by DNA methylation of paired boxed gene 1 (PAX1). Diagn Cytopathol. 2013 Jan;41(1):41-6. doi: 10.1002/dc.21758. Epub 2011 Jun 27.</citation>
    <PMID>21710649</PMID>
  </reference>
  <reference>
    <citation>Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer. 2001 Feb 25;93(1):8-15.</citation>
    <PMID>11241260</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>November 12, 2015</last_update_submitted>
  <last_update_submitted_qc>November 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DNA methylation</keyword>
  <keyword>Cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

